Fresenius Medical Care AG Faces “Sell” Rating Amid Rising Dialysis Competition
Fresenius Medical Care AG receives a “sell” rating amid rising dialysis‑market competition and regulatory pressure, with stable stock amid broader EU equity trends.
2 minutes to read









